Advertisement
Advertisement
TOPIC

Biomedicine: Geopolitics

Related Topics:
Biomedicine: Geopolitics
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
A general view of Guangzhou. The Hong Kong and Macau Affairs Office arranged a six-day trip spanning the Greater Bay Area. Photo: Eugene Lee
Hong Kong economy

Chinese tech, pharma firms eye Hong Kong as springboard for global expansion

Industry leaders highlight city’s international reach and expertise as state-owned drug maker considers Northern Metropolis project investment.

China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Banking & finance

China biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny

China economy

Outside In | China’s export success is a by-product of self-reliance

But while the export surge is an accidental consequence of self-sufficiency and competitive manufacturers, the solution is not protectionism.

videocam
7
Containers sitting stacked at the Port of Shanghai on July 14 in China. Photo: VCG via Getty Images
Science

China biotech sector fears policy backlash after girl dies in gene-editing trial

Scientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’.

videocam
US-China trade war

Record Chinese biotech out-licensing meets rising US scrutiny

Surging cross-border deals out of China are running headlong into intensifying US national security fears.

videocam
22
Advertisement
Advertisement
Advertisement
Banking & finance

As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec

Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.

WuXi AppTec was expected to release its half-year earnings results on August 3. Photo: Handout
China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

videocam
Banking & finance

Mainland funds boost stakes in Hong Kong-listed biotech amid value dislocation

Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply.

China manufacturing

The next rare earths? Why US fears another Chinese manufacturing advantage

China’s production of drug inputs has boomed in recent years, increasing market share and prompting fears of weaponisation in Washington.

videocam
26
Illustration: Victor Sanjinez
US-China relations

US National Science Foundation to ban projects with flagged Chinese institutions

Raising security fears, NSF moves from case-by-case approval to full ban on working with restricted entities and their employees.

The US National Science Foundation is moving away from Chinese collaborators that have been flagged as restricted entities by the government. Photo: Shutterstock
China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

China’s private sector

Hong Kong draws royalties giant as mainland China biotech licensing heats up

Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.

China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

Cancer research being conducted in a modern lab. Cancer treatments remained the top focus of the record 5,215 clinical drug trials in China last year. Photo: Shutterstock
Medicine

China closing in but US leads in biotech quality and commercial reach: survey

The Cure survey said China leads ⁠in clinical development and supply chain, and rated US funding cuts a bigger threat than China competition.

videocam
A scientist works with a microscope and test tubes in a research laboratory. Photo: Shutterstock
China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

Advertisement
Advertisement
Advertisement
China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

The cost advantages of Chinese pharmaceuticals mean they still appeal to multinational drug makers despite US security concerns. Photo: TNS
China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

US-China trade war

The next tech war? Why biotech may become a new US-China battleground

China’s biotech industry is rapidly moving up the value chain, prompting fears in the US and calls for tighter controls.

videocam
13
China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Illustration of a healthy lung and a smoker's lung. Photo: Shutterstock
US-China relations

Opinion | How US tech hegemony is locking out the Global South

The world deserves better than a monopoly that builds walls and hobbles development.

videocam
4
Illustration: Craig Stephens
China’s private sector

Chinese drug makers take on Western dominance in US$16 billion Parkinson’s race

The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
Biomedicine: Companies

Global drug makers face pricing pressure as China targets affordable healthcare

As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.

5
A pharmaceutical production line in Meishan, China. Photo: Costfoto/NurPhoto via Getty Images
China’s private sector

Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline

Sequencio, CK Life’s new Hong Kong unit, is advancing about 20 cancer vaccine projects as China pathway offers faster route to human trials.

Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement